The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update and Financing

4 May 2020 07:00

RNS Number : 7387L
Premier Veterinary Group PLC
04 May 2020
 

 

 

PREMIER VETERINARY GROUP PLC

 

("PVG", the "Company" or the "Group")

 

Business Update and Financing

 

 

London, UK, 4 May 2020 - Premier Veterinary Group PLC (LSE: PVG)

Business Update

The unaudited consolidated management accounts for the six months ended 31 March 2020 show a 5.2% increase in revenues to £1,965,000 (31 March 2019: £1,867,000) and a significant improvement in the group's loss from operations before interest and tax to £(842,000) (31 March 2019 £(1,390,000)).

For the same period PVG achieved a 22% increase in the number of revenue generating pets on active plans to 336,000 (31 March 2019: 275,000).

As part of the continual development of functionality within its integrated multi-currency platform, PVG launched a home delivery offering in the UK during April 2018 (branded as Post2Pet™). The service has been particularly well received by clinics and pet owners alike following the Government lock-down announced on 23 March 2020. Post2Pet™ has enabled the continued supply of important medicines to pet owners during this period when limitations have been imposed on veterinary clinics and the movement of people.

Notwithstanding the impact of the Coronavirus (Covid-19) pandemic on PVG's business (which may result in slower growth and increased cancellations by pet owners) revenues for the month of April 2020 were 1.8% higher than February (being the last full month prior to the UK lockdown) and the number of pets on plan increased slightly during this period.

 

In view of the global uncertainties PVG has considered the assistance available from government agencies in the UK, US and France and has accessed that assistance where appropriate including the furloughing of a small number of employees. PVG's remaining employees including the directors have agreed to a Group wide reduction in salaries from April to June and other short-term cost savings have been implemented.

Financing

Bybrook Finance Solutions Limited (BFSL) has provided loan finance to PVG pursuant to a facility agreement dated 25 January 2019 (as amended by a supplemental deed of amendment dated 23 December 2019 and a second supplemental deed of amendment dated 29 January 2020) (the 2019 Facility) and a facility agreement dated 29 January 2020 (the 2020 Facility).

The 2020 Facility provided for loan finance of £1.1m of which £600,000 was drawn down in January 2020 with a repayment date of 30 April 2020. The draw-down of the remaining facility and the extension of the repayment date to 31 July 2021 was subject to the issue by PVG of warrants to subscribe for up to 383,673 new PVG ordinary shares of 10p each at an exercise price of 10p per share within 5 years of the issue of any such warrants (the Warrants). As a result of the occurrence of the Coronavirus (Covid-19) pandemic and the imposition of a lock down by the UK Government PVG's Annual General Meeting due to take place on 31 March 2020 was postponed and the Warrants could not be issued because PVG did not have a valid authority to issue shares. Accordingly the repayment date was not extended and BFSL no longer has an obligation to make any further advances to PVG under the 2020 Facility.On 1 May 2020 PVG and BFSL entered into further deeds of amendment that provide for (i) the waiver of events of default that have occurred under the 2019 Facility and the 2020 Facility as a result of actions taken by PVG in light of the Coronavirus (Covid-19) pandemic and (ii) the extension of the repayment date in the 2020 Facility to 31 July 2021.

Rajan Uppal the sole director and shareholder of BFSL is a director of PVG and has an interest in 5,421,138 Ordinary Shares in PVG representing 35.3% of PVG's issued share capital.

Crossroads Finance limited ("Crossroads"), a company jointly owned and controlled by Dominic Tonner, Chief Executive Officer of PVG, and his spouse has provided funding to BFSL linked to BFSL's loans to PVG.

Dominic Tonner has an interest in 1,799,670 Ordinary Shares in PVG, representing 11.73% of PVG's issued share capital.

Annual General Meeting (AGM)

PVG continues to review options for holding the AGM as soon as is practically and safely possible and we anticipate further guidance from the Department for Business, Energy and Industrial Strategy and the Financial Reporting Council to provide clarity in that regard with new legislation to allow an AGM to proceed.

Outlook

The Coronavirus (Covid-19) pandemic has created uncertainties which make it more difficult for many businesses including PVG to forecast with any degree of certainty. However the directors of PVG believe that the nature of PVG's business and its continued willingness to invest in its technology platform and people even in these difficult times will lead to continued albeit slower growth and that PVG has sufficient working capital for the foreseeable future.

 

-Ends-

 

For further information, please contact:

 

Premier Veterinary Group plc

Dominic Tonner, Chief Executive Officer Tel: +44 (0)117 970 4130

Andrew Paull, Chief Financial Officer

 

For further details go to: www.premiervetgroup.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDZZGGKNFZGGZM
Date   Source Headline
6th Sep 20134:40 pmRNSSecond Price Monitoring Extn
6th Sep 20134:35 pmRNSPrice Monitoring Extension
6th Sep 201312:54 pmRNSHolding(s) in Company
4th Sep 20134:40 pmRNSSecond Price Monitoring Extn
4th Sep 20134:35 pmRNSPrice Monitoring Extension
2nd Sep 201312:00 pmRNSHolding(s) in Company
29th Aug 20134:41 pmRNSSecond Price Monitoring Extn
29th Aug 20134:35 pmRNSPrice Monitoring Extension
29th Aug 20139:00 amRNSHalf Yearly Report
16th Aug 20134:40 pmRNSSecond Price Monitoring Extn
16th Aug 20134:35 pmRNSPrice Monitoring Extension
15th Aug 20135:32 pmRNSHolding(s) in Company
14th Aug 20134:56 pmRNSHolding(s) in Company
30th Jul 20134:40 pmRNSSecond Price Monitoring Extn
30th Jul 20134:35 pmRNSPrice Monitoring Extension
23rd Jul 20133:44 pmRNSHolding(s) in Company
9th Jul 20132:00 pmRNSCompany Update
8th Jul 20134:40 pmRNSSecond Price Monitoring Extn
8th Jul 20134:35 pmRNSPrice Monitoring Extension
5th Jul 201310:48 amRNSHolding(s) in Company
5th Jul 20137:00 amRNSCompany Update
27th Jun 20134:40 pmRNSSecond Price Monitoring Extn
27th Jun 20134:35 pmRNSPrice Monitoring Extension
25th Jun 20132:05 pmRNSResults of Annual General Meeting
14th Jun 20134:40 pmRNSSecond Price Monitoring Extn
14th Jun 20134:35 pmRNSPrice Monitoring Extension
4th Jun 20132:48 pmRNSBlocklisting Six Monthly Return
24th May 20134:40 pmRNSSecond Price Monitoring Extn
24th May 20134:35 pmRNSPrice Monitoring Extension
17th May 20137:00 amRNSInterim Management Statement
16th May 20131:20 pmRNSHolding(s) in Company
8th May 20136:09 pmRNSHolding(s) in Company
8th May 20135:47 pmRNSHolding(s) in Company
2nd May 20131:45 pmRNSHolding(s) in Company
1st May 20134:35 pmRNSPrice Monitoring Extension
30th Apr 20137:00 amRNSFinal Results
26th Apr 20134:50 pmRNSHolding(s) in Company
24th Apr 20133:47 pmRNSHolding(s) in Company
26th Mar 20134:40 pmRNSSecond Price Monitoring Extn
26th Mar 20134:35 pmRNSPrice Monitoring Extension
22nd Mar 201311:50 amRNSHolding(s) in Company
20th Mar 20131:15 pmRNSHolding(s) in Company
19th Mar 201311:34 amRNSForm 8.3 - Ark Therapeutics
19th Mar 20139:47 amRNSHolding(s) in Company
18th Mar 20131:54 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Mar 201312:01 pmRNSTermination of Offer Period and Rule 10.8 Waiver
7th Mar 20134:22 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 20133:04 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 201310:02 amRNSForm 8.3 - Ark Therapeutics Group Plc
1st Mar 201311:49 amRNSForm 8.3 - Ark Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.